Back pain treatment OrthoSon appoints NED to help growth

OrthoSon Nick Birch

Oxford-based OrthoSon, which is developing minimally invasive and motion-restoring treatments for low back pain based on ultrasound and in-situ curing hydrogel implants, has appointed of spine consultant Mr Nick Birch FRCS (Orth) to its Board as a Non-Executive Director.

Mr Birch, formerly a clinical advisor to the company, is also Chairman of the company’s Clinical Advisory Group. The Group will help steer OrthoSon as it refines its clinical development strategy. Targeting a market worth in excess of $1bn, the company expects its spinal disc restoration approach to be disruptively cost effective and safe compared with gold standard surgical approaches, allowing patients to be treated on a day-case basis.

Mr Birch is a Consultant spinal specialist and has a particular expertise in diagnosing and treating complex pain and neurological disorders associated with the spine. With an interest in innovative solutions to treat spinal pain associated with disc degeneration, he has advised on the development of several bone and disc repair technologies. Mr Birch is a Fellow of the Royal College of Surgeons of England, a Fellow of the British Orthopaedic Association, and holds memberships of the British Associations of Spine Surgeons, the North American Spine Society and the Society for Back Pain Research.

Drs Aaron Calodney MD and Kris Radcliff MD join Mr Birch in the Clinical Advisory Group. Both based in the US, they are active in spinal pain management and spinal surgery respectively and have previously been advisors to OrthoSon. The company is expecting to grow the group in due course.

Nick  said, ‘The combination of OrthoSon’s hydrogel and ultrasound-based technologies has huge potential to restore disc motion and improve the quality of life for sufferers of low back pain, the largest cause of disability globally. I’m delighted to join the company’s Board and chair the Clinical Advisory Group as the development of its technology progresses.’

Rich Simmonds, CEO of OrthoSon, said, ‘Nick has given us valuable counsel for several years and we are pleased to welcome him to the OrthoSon Board as we refine our clinical development strategy. Formation of the Clinical Advisory Group, which he chairs, reflects our progress towards first-in-human studies.’